{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:54:00Z","timestamp":1791327240172,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejoncologynursing.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejon.2026.103332","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:54:29Z","timestamp":1790265269000},"page":"103332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Developing a patient and healthcare provider pragmatic guide approach to standardize adverse event management with targeted therapy"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2751-3349","authenticated-orcid":false,"given":"Jessica","family":"Reibel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezia","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejon.2026.103332_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating tumor DNA-guided De-Escalation targeted therapy for advanced non\u2212small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejon.2026.103332_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.eprac.2025.03.016","article-title":"A real-world pharmacovigilance analysis of lorlatinib-associated metabolic effects using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024","volume":"31","author":"Frey","year":"2025","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ejon.2026.103332_bib3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejon.2026.103332_bib4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00228-020-02897-x","article-title":"Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study","volume":"76","author":"Han","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejon.2026.103332_bib5","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.3390\/ijms24119429","article-title":"Targeted toxicities: protocols for monitoring the adverse events of targeted therapies used in the treatment of non-small cell lung cancer","volume":"24","author":"Hines","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejon.2026.103332_bib6","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.18632\/oncotarget.23840","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejon.2026.103332_bib7","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.ejon.2026.103332_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","article-title":"Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study","volume":"13","author":"Luo","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejon.2026.103332_bib9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ajhp\/zxac038","article-title":"Impact of a pharmacist-led telehealth oral chemotherapy clinic","volume":"79","author":"Mathur","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejon.2026.103332_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2021.06.002","article-title":"The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer","volume":"160","author":"Melosky","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejon.2026.103332_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejon.2026.103332_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/cancers17030353","article-title":"Emerging targeted therapies in non-small-cell lung cancer (NSCLC)","volume":"17","author":"Mina","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejon.2026.103332_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108662","article-title":"Managing lorlatinib together: an overview and practical guide for patients by ALK-positive NSCLC patients and medical experts","volume":"206","author":"Pronsati","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejon.2026.103332_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/OP.23.00452","article-title":"Direct clinical pharmacist-patient telephone follow-up: a focus on GI medical oncology symptom management","volume":"20","author":"Rogers","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ejon.2026.103332_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejon.2026.103332_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejon.2026.103332_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejon.2026.103332_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/joim.13445","article-title":"Complications following novel therapies for non\u2010small cell lung cancer","volume":"291","author":"Skribek","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejon.2026.103332_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced Non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejon.2026.103332_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejon.2026.103332_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388926002371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388926002371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:48:49Z","timestamp":1791326929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388926002371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S1462388926002371"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2026.103332","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a patient and healthcare provider pragmatic guide approach to standardize adverse event management with targeted therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejon.2026.103332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103332"}}